Pronefra for Cats & Dogs: Complete Guide – How It Works, Dosage by Weight, Bottle Duration & How It Fits Into CKD Management

Pronefra is Virbac’s palatable 5-in-1 oral suspension for supporting kidney function in cats and dogs with chronic kidney disease (CKD). If your pet has been diagnosed with CKD, elevated phosphorus, or early kidney insufficiency, this guide explains exactly how each ingredient works, how much to give based on body weight, how long each bottle will last, and how Pronefra fits into the broader picture of CKD management.

What Is Chronic Kidney Disease and Why Does Phosphorus Matter?

Chronic kidney disease (CKD) is the gradual, irreversible loss of kidney function. It is one of the most common serious conditions in cats over 10 years old, affecting up to 30% of senior cats and around 7% of dogs. In over 70% of affected cats, the disease presents as weight loss, reduced appetite, increased thirst and urination, vomiting, and lethargy.

As kidney function declines, two particular problems emerge that Pronefra is specifically designed to address:

1. Phosphorus Accumulation (Hyperphosphataemia)

Healthy kidneys filter and excrete phosphorus from the blood. In CKD, this filtration capacity is reduced. Phosphorus builds up in the bloodstream — a condition called hyperphosphataemia. This is dangerous for two reasons: first, elevated phosphorus directly damages remaining kidney tissue through mineralisation of renal cells; second, it triggers excessive parathyroid hormone secretion (renal secondary hyperparathyroidism), which causes bone loss and cardiovascular complications. Controlling phosphorus is one of the most evidence-supported interventions in CKD management.

2. Uraemic Toxin Accumulation

The kidneys also filter metabolic waste products — urea, creatinine, indoxyl sulphate, and other uraemic toxins — from the blood. As function declines, these accumulate systemically. This uraemia is responsible for the nausea, vomiting, reduced appetite, and lethargy that characterise moderate-to-advanced CKD.

How Pronefra’s 5 Ingredients Address These Problems

Calcium Carbonate + Magnesium Carbonate: Dual Intestinal Phosphate Binders

Both carbonate salts work in the gastrointestinal tract, binding to dietary phosphorus — released from food during digestion — to form insoluble calcium/magnesium phosphate complexes that cannot be absorbed. Instead of entering the bloodstream and accumulating, the phosphorus is carried out of the body in the faeces. Using two binders simultaneously provides broader, more effective phosphorus reduction than either alone.

Critically, intestinal phosphate binders must be given with food to be effective. Phosphorus is only present in the gut in significant amounts during and after a meal. A phosphate binder given between meals binds to very little phosphorus. This is why Pronefra’s dosing instructions specify administration at or around mealtimes.

Chitosan: Uraemic Toxin Binder

Chitosan is a natural polysaccharide derived from crustacean shells with a strong positive charge that attracts negatively charged uraemic toxin molecules (particularly urea and related compounds) in the gut. By binding these toxins before they are absorbed, chitosan reduces circulating uraemic toxin levels, relieving some of the toxaemia that drives CKD symptoms.

Marine Oligopeptides (Fish Protein Hydrolysate): ACE-Inhibiting Peptides

Marine oligopeptides are short peptide chains derived from fish protein that inhibit angiotensin-converting enzyme (ACE) — the enzyme that produces angiotensin II, a potent vasoconstrictor that raises blood pressure and directly damages the glomeruli (filtering units) of the kidney. Hypertension complicates CKD in up to 65% of cats. It accelerates glomerular damage through a self-reinforcing cycle of renal injury. The ACE-inhibiting peptides in Pronefra provide blood pressure support through the same pathway as prescription ACE inhibitors like benazepril (Fortekor), though Pronefra is a supplement, not a substitute for prescription antihypertensive therapy in confirmed hypertensive patients.

Astragalus Polysaccharides: Renal Structure Support

Polysaccharides from Astragalus membranaceus have nephroprotective properties documented in experimental studies, including antioxidant activity, anti-inflammatory effects, and reduction of glomerular damage. These polysaccharides contribute to maintaining the normal structural integrity of the kidney.

Clinical Evidence

A published clinical study (Journal of Applied Research in Veterinary Medicine, 2014) evaluated Pronefra over 12 weeks in 10 cats given the supplement alongside their normal food. The results showed statistically significant improvements in key renal biomarkers:

• Plasma phosphorus decreased significantly (p=0.002) — the primary intended effect of the phosphate binders
• Plasma creatinine decreased significantly (p=0.016) — a marker of improved kidney filtration
• Fractional excretion of phosphorus was significantly lower at the end of the study (p=0.02) — indicating reduced renal phosphorus burden

These results provide clinical support for Pronefra’s efficacy as a renal support supplement in cats with CKD.

Complete Dosage Guide

Give twice daily at or around mealtimes. Fresh water should be available at all times. Shake the bottle vigorously before each use — light sedimentation is normal.

Weight-Based Reference Table

Which size to buy: For cats and small dogs, the 60ml bottle covers approximately one month per cat at standard doses — good for initial trials. For long-term supplementation in cats, the 180ml provides 2–3 months and is significantly more economical. For dogs over 10kg on ongoing supplementation, the 180ml is strongly recommended.

How to Use the Dosing Syringe

1. Shake the bottle vigorously before use
2. Unscrew the white cap; screw on the blue cap
3. Keep bottle upright, open the blue cap, insert syringe tip firmly
4. Invert the bottle; pull the plunger to the correct volume mark
5. Return bottle upright and twist to remove the syringe
6. Add to food or give directly into the mouth
7. Replace blue cap and white cap after use

Where Pronefra Fits in CKD Management

Pronefra is a nutritional supplement, not a prescription medicine. It is best understood as part of a comprehensive CKD management plan that typically includes:

• Renal diet (Hill’s k/d, Royal Canin Renal, Purina NF) — reduces dietary phosphorus intake; the first-line phosphorus management strategy
• Pronefra — adds intestinal phosphate binding for animals where diet alone doesn’t achieve target phosphorus levels, plus uremic toxin binding and blood pressure support
• Prescription ACE inhibitors (benazepril/Fortekor) — for confirmed proteinuria or hypertension; not replaced by Pronefra but can be complementary
• Fluid therapy — subcutaneous fluids for dehydration management in moderate-to-advanced CKD
• Regular monitoring — blood and urine checks every 3–6 months to track phosphorus, creatinine, SDMA, blood pressure, and protein/creatinine ratio

The IRIS (International Renal Interest Society) guidelines recommend initiating phosphate restriction from IRIS Stage 2 onwards. Pronefra is particularly valuable when renal diet alone is not achieving IRIS-recommended phosphorus targets (typically <1.45 mmol/L in cats, <1.6 mmol/L in dogs for Stage 2).

Where to Buy Pronefra

You can order Pronefra 60ml or 180ml from PetShopBoss.com with free worldwide shipping.

Related: Fortekor Plus (Benazepril) – ACE Inhibitor for Cardiac & Renal Patients | Cerenia Injectable – Anti-nausea Treatment for CKD-related Vomiting